for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akeso Inc

9926.HK

Latest Trade

44.30HKD

Change

1.70(+3.99%)

Volume

1,321,000

Today's Range

42.60

 - 

44.60

52 Week Range

28.00

 - 

69.90

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
42.60
Open
43.00
Volume
1,321,000
3M AVG Volume
71.94
Today's High
44.60
Today's Low
42.60
52 Week High
69.90
52 Week Low
28.00
Shares Out (MIL)
817.06
Market Cap (MIL)
33,581.05
Forward P/E
-33.47
Dividend (Yield %)
--

Next Event

Akeso Inc Annual Shareholders Meeting

Latest Developments

More

Akeso Says To Repurchase Shares In Open Market From Time To Time To Use Up To Hk$100 Million

Akeso Says PD-1/VEGF Bi-Specific Antibody Obtained Approval To Initiate Phase 2 Clinical Trial

Akeso Gets Approval To Advance Phase Ii Clinical Trial Of Il-4R Monoclonal Antibody To Treat Atopic Dermatitis And Asthma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akeso Inc

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No.6 Shennong Road

Huoju Development Zone

Zhongshan, GNG

528437

China

+86.760.89873936

http://www.akesobio.com/

Executive Leadership

Yu Xia

Executive Chairwoman of the Board, President, Chief Executive Officer

Xiaojie Xi

Chief Financial Officer, Joint Company Secretary

Baiyong Li

Senior Vice President, Chief Scientific Officer, Executive Director

Zhongmin Wang

Senior Vice President, Executive Director

Yu Xia

Senior Vice President, Executive Director

Key Stats

1.54 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2021(E)

0.4K
EPS (CNY)

2021(E)

-0.977
Price To Earnings (TTM)
--
Price To Sales (TTM)
213.44
Price To Book (MRQ)
7.10
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.73
LT Debt To Equity (MRQ)
11.38
Return on Investment (TTM)
-25.48
Return on Equity (TTM)
-22.60

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up